The AI in drug discovery market is rapidly growing as pharmaceutical and biotechnology companies turn to artificial intelligence to accelerate research and development. AI tools help analyze complex biological data, identify promising drug candidates, and predict outcomes with greater accuracy—reducing time and costs associated with traditional drug discovery. Applications range from target identification and molecule design to clinical trial optimization. As healthcare and technology continue to converge, AI is transforming how drugs are discovered, offering faster innovation and more personalized treatment possibilities.
According to Fortune Business Insights, the global artificial intelligence (AI) in drug discovery market was valued at USD 3.00 billion in 2022 and is projected to grow from USD 3.54 billion in 2023 to USD 7.94 billion by 2030, exhibiting a CAGR of 12.2% during the forecast period (2023–2030). In 2022, North America dominated the AI in drug discovery market with a market share of 69.33%.
In November 2022, Cyclica secured a USD 1.8 million grant from the Bill & Melinda Gates Foundation to enhance its AI-driven drug discovery platform—a move aimed at discovering non-hormonal contraceptives using low-data biological targets. This grant underscores the increasing investment in AI-based drug discovery technologies.